S.B. NO. 1394

JAN 2 5 2023 A BILL FOR AN ACT

RELATING TO METHADONE TREATMENT PROGRAMS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-40, Hawaii Revised Statutes, is 2 amended to read as follows:

3 "§329-40 Methadone treatment programs. (a)

4 Notwithstanding any other provision of law to the contrary, 5 methadone may be administered or dispensed or both as part of a 6 state-registered and federal Substance Abuse and Mental Health Services Administration approved methadone treatment program by 7 8 a practitioner who is licensed and registered under state and federal law to administer and dispense methadone for patients or 9 10 by an agent of the practitioner, supervised by and under the 11 order of the practitioner. The agent must be a pharmacist, 12 registered nurse, or licensed practical nurse. The licensed 13 practitioner shall be responsible for the amounts of methadone 14 administered or dispensed in accordance with Substance Abuse and 15 Mental Health Services Administration regulations and shall 16 record, approve, and countersign all changes in dosage 17 schedules.

Page 2

S.B. NO.<u>1394</u>

1 (b) Registration of a methadone treatment program requires
2 that:

3	(1)	The methadone treatment program obtain a controlled
4		substance registration from the State of Hawaii and
5		the Drug Enforcement Administration;

6 (2) The medical director of a methadone treatment program
7 obtain a controlled substance registration from the
8 State of Hawaii and the Drug Enforcement

9 Administration at the location of the program;

10 (3) Admission to a methadone treatment program be limited
11 to the narcotic-dependent persons as defined in this
12 chapter;

13 (4)Unless otherwise stated in this chapter, admission to 14 a methadone treatment program be in accordance with 15 Title 21 Code of Federal Regulations Part 291 and Title 42 Code of Federal Regulations Part 8; 16 17 All medical orders including initial medication (5) 18 orders, all subsequent medication order changes, all 19 changes in the frequency of take-home medication, and 20 the prescription of additional take-home medication for emergency situations be authorized by a licensed 21 22 registered physician employed by the program;

S.B. NO. <u>1394</u>

1	(6)	Only the medical director or other designated program		
2		physician authorize a patient's admission for		
3		treatment in accordance with Title 21 Code of Federal		
4		Regulations Part 291 and Title 42 Code of Federal		
5		Regulations Part 8; and		
6	(7)	Take-home doses of methadone be dispensed to patients		
7		in accordance with Title 21 Code of Federal		
8		Regulations Part 291 and Title 42 Code of Federal		
9		Regulations Part 8, but shall not exceed a fourteen-		
10		day supply at any given time nor more than the maximum		
11		amount of take-homes for Levo-alphacetylmethadol		
12		(LAAM/Orlamm) that would allow a patient to be away		
13		from the clinic for dosing for more than two weeks		
14		unless authorized by the state authority.		
15	(C)	Before admitting an applicant to a methadone treatment		
16	program,	the medical director shall conduct a medical evaluation		
17 that requires testing as follows:				
18	(1)	Laboratory test for determination of hepatitis C virus		
19		infection, unless the medical director has determined		
20		the applicant's subcutaneous veins are severely		
21		damaged to the extent that a blood specimen cannot be		
22		obtained; or		

PSD-04(23)

Page 4

S.B. NO.<u>1394</u>

1	(2)	Waived test for determination of hepatitis C virus
2		exposure, followed by a laboratory confirmatory test
3		for determination of hepatitis C virus infection;
4	<u>(d)</u>	The program shall have policies and procedures in
5	place for	screening, and referrals for care, and curative
6	treatment	(either on-site or to external partners).

7 The term "methadone treatment program" as used in this 8 section means an organization or a person (including a private 9 physician) that administers or dispenses methadone to a 10 narcotic-dependent person for maintenance or detoxification 11 treatment and who provides the medical and rehabilitative 12 services required by Title 21 Code of Federal Regulations Part 13 291 or Title 42 Code of Federal Regulations Part 8 and is 14 approved to do so by the State and by the United States Substance Abuse and Mental Health Services Administration, and 15 16 who holds a controlled substance registration as required by this chapter and the United States Drug Enforcement 17 18 Administration to use methadone for the treatment of narcotic-19 dependent persons.

20 The term "narcotic-dependent person" as used in this21 section means an individual who physiologically needs heroin or

16

S.B. NO. <u>1394</u>

a morphine-like drug to prevent the onset of signs of
 withdrawal.

3 The term "state authority" as used in this section means
4 the agency within the State [which] that exercises the
5 responsibility for governing the treatment of narcotic-dependent
6 persons with the narcotic drug methadone.

7 The term "waived test" as used in this section means a 8 Clinical Laboratory Improvement Amendments of 1988-waived point-9 of-care ("rapid") test for determination of hepatitis C 10 infection." 11 SECTION 2. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored. 12 13 SECTION 3. This Act shall take effect upon its approval. 14 INTRODUCED BY: MMM-M. 15

BY REQUEST

S.B. NO. <u>1394</u>

٪

Report Title: Methadone Treatment Programs; Hepatitis Testing

Description:

Amends section 329-40, Hawaii Revised Statutes, to require the medical director of a methadone treatment program to conduct a medical evaluation that offers testing for Hepatitis C exposure and infection. Requires that a methadone treatment program have policies and procedures in place for screening and referrals to care and curative treatment.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

SB. NO. 1394

JUSTIFICATION SHEET

- DEPARTMENT: Public Safety
- TITLE: A BILL FOR AN ACT RELATING TO METHADONE TREATMENT PROGRAMS.
- PURPOSE: To require that the medical director of a methadone treatment program conduct a medical evaluation that offers testing for Hepatitis C exposure and infection, and to require that a methadone treatment program have in place policies and procedures for the screening and referrals for care and curative treatment
- MEANS: Amend section 329-40, Hawaii Revised Statutes (HRS).
- JUSTIFICATION: The proposed bill seeks to quell the growing spread of Hepatitis C in our communities by increasing the detection of Hepatitis C infection and exposure and increasing opportunities to refer patients for curative treatment.

<u>Impact on the public:</u> This bill is intended to provide greater protection to the public by increasing the detection of Hepatitis C infection and exposure, increasing curative treatment, and reducing the prevalence of infection in the community.

Impact on the department and other agencies: The proposed measure would provide needed assistance to the Department of Health and private harm reduction agencies in their efforts to reduce the spread of Hepatitis C in the community.

GENERAL FUND: None.

OTHER FUNDS: None.

SB. NO. 1394

PPBS PROGRAM DESIGNATION: P

PSD 502.

OTHER AFFECTED AGENCIES: Depa

Department of Health.

EFFECTIVE DATE: Upon approval.